A direct comparison of the two inhibitors revealed a slight superiority of anti-LAG-3 over anti-PD-L1, potentially due to the presence of LAG-3+T-cells at early tumor stages, whereas PD-L1 plays a more functionally relevant role at later stages. The gene discussed is LAG3; the disease is neoplasm.